



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com

Website : www.concorddrugs.in

To,

Date: 14.11.2019

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai- 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.11.2019

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Thursday, 14.11.2019 at 05.00 p.m. at the registered office of the company, the Board considered and approved Un-Audited financial results along with Limited Review report for the quarter and half year ended 30.09.2019 (enclosed).

The meeting concluded at **05.15** p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Chairman
DIN: 01764665



Encl: as above



Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 September 2019, and the year to date results for the period 1 April 2019 to 30 September 2019, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six month period ended 30 September 2018 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and



other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N.G Rao and Associates
Chartered Accountants
FRN:009399S



(G Nageswara Rao)
Partner
MNo:207300

Place:Hyderabad
Date:14-11-2019 .

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana
Balance sheet as at 30th Sep 2019

Particulars	Note	As at Sep 30, 2019	As at March 31, 2019
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	1,035.01	1,106.32
(b) Capital Work-in Progress	3	56.08	28.89
(b) Investment property	3	78.60	78.60
Financial assets			
(a) Loans & Advances	5	50.02	50.02
(b) Trade receivables	6		
Other Non current assets	4	42.50	39.26
Total Non - Current Assets		1,262.21	1,303.08
Current Assets			
Inventories	7	1,741.09	1,864.15
Financial assets			
(a) Investments			
(b) Trade receivables	6		
(c) Cash and cash equivalents	8	4,084.44	4,843.47
(d) Bank balances other than (c) above	8	2.98	15.89
(e) Other Current Financial Assets	9	2.59	2.59
Other current assets	10	4.13	4.13
Total Current assets		212.78	243.53
		6,048.01	6,973.77
Total Assets		7,310.22	8,276.85
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	874.38	786.18
Other equity	12	1,460.34	1,529.46
Total Equity		2,334.71	2,315.63
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	70.00	68.97
(b) Trade payables			
Deferred tax liabilities, net	14	13.18	12.79
Provisions	15	208.38	217.23
Government Grants	13	49.83	54.13
Total Non-current liabilities		341.39	353.13
Current liabilities			
Financial liabilities			
(a) Borrowings	16	912.75	913.68
(b) Trade payables	17	3,284.50	4,263.73
(c) Other Current financial liabilities	18		
Current tax liabilities, net	15	18.94	11.72
Other current liabilities	19	417.91	418.96
Total Current liabilities		4,634.11	5,608.09
Total liabilities		4,975.51	5,961.22
Total Equity and liabilities		7,310.22	8,276.85



S. N. S. Nay

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th September 2019

Particulars	[Rs. in Lakhs]					
	Quarterly ended			Half Year Ended		Year ended
	30-Sep-19 (Unaudited)	30-Jun-19 (Unaudited)	30-Sep-18 (Unaudited)	30.09.2019 (Unaudited)	30.09.2018 (Unaudited)	31-Mar-19 (Audited)
I Revenue from Operations						
a. Net sales from Operations	1,409.43	1,331.07	1,149.10	2,740.51	2,452.28	4,807.72
b. Other Operating Income						
II Other Income	2.15	3.15	1.90	5.31	4.52	8.59
III Total Revenue (I+II)	1,411.59	1,334.22	1,151.00	2,745.81	2,456.80	4,816.31
IV Expenses						
a. Cost of Material Consumed:						
b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,118.05	1,094.90	760.96	2,212.95	1,945.54	3,913.85
c. Employees Benefit Expenses	52.36	21.30	164.69	73.66	73.47	45.59
d. Finance Costs	94.99	81.36	84.46	176.34	137.18	252.92
e. Depreciation and Amortisation expense	44.62	42.69	38.95	87.32	80.43	159.30
f. Other expenses	36.84	36.39	54.81	73.22	108.97	171.18
Total Expenses	56.33	39.30	42.20	95.63	99.18	229.50
V Profit/ (Loss) before Exceptional item and tax (III-IV)	1,403.19	1,315.93	1,146.07	2,719.12	2,444.76	4,772.33
VI Exceptional Items	8.40	18.30	4.93	26.69	12.04	43.98
VII Profit/ (Loss) before tax (V-VI)	8.40	18.30	4.93	26.69	12.04	43.98
VIII Tax Expense:						
a. Current tax	2.75	4.87	1.20	7.61	(4.46)	3.27
b. Deferred tax charge/credit	2.55	4.68	8.92	7.23	10.38	11.72
c. MAT Credit	0.20	0.19	7.72	0.38	14.83	8.44
IX Profit/ (Loss) for the period (VII-VIII)	5.65	13.43	3.73	19.08	16.50	40.70
X Other Comprehensive Income						
Items that will not be reclassified to profit or loss						
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	5.65	13.43	3.73	19.08	16.50	40.70
XI Paid-up equity share capital						
(Face value of the share- Rs. 10 each)	874.38	874.38	786.18	874.38	786.18	786.18
Other Equity						
XII Earnings per share (of Rs. 10 each)	1,460.34	1,444.22	1,146.14	1,460.34	1,146.14	1,529.46
XIII a. Basic (in Rs)	0.06	0.15	0.05	0.22	0.21	0.52
b. Diluted (in Rs)	0.06	0.15	0.05	0.22	0.21	0.52

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) Prescribed under section 133 of the companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14th November, 2019
- The company operates in only one Segment viz., "Pharmaceutical Products"
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.

Place: Hyderabad
Date: 14-11-2019



S.N. →

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana
Statement Of Standalone Profit and Loss for the year ended 30th Sep 2019 Rs. In Lakhs

	Particulars	Note	As at Sep 30, 2019	As at March 31, 2019
I	Revenue from Operations			
	a. Net sales from Operations	20	2,740.51	4,807.72
	b. Other Operating Income			-
II	Other Income	21	5.31	8.59
III	Total Revenue (I+II)		2,745.81	4,816.31
IV	Expenses			
	a. Cost of Material Consumed	22	2,212.95	3,913.85
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	73.66	45.59
	c. Employees Benefit Expenses	24	176.34	252.92
	d. Finance Costs	25	87.32	159.30
	e. Depreciation and Amortisation expense	3	73.22	171.18
	f. Other expenses	26	95.63	229.50
	Total Expenses		2,719.12	4,772.33
V	Profit/ (Loss) before Exceptional item and tax (III-IV)		26.69	43.98
VI	Exceptional Items		-	-
VII	Profit/ (Loss) before tax (V-VI)		26.69	43.98
VIII	Tax Expense:			
	a. Current tax		7.61	3.27
	b. Deferred tax charge/credit		7.23	11.72
			0.38	-8.44
IX	Profit/ (Loss) for the period (VII-VIII)		19.08	40.70
X	Other Comprehensive Income			
	Items that will not be reclassified to profit or loss		-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		19.08	40.71
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		874.38	786.18
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		0.22	0.52
	b. Diluted (in Rs)		0.22	0.52



S. N. S.

Statement of Cash flow for the six months period ended 30 september, 2019

Rs in Lakhs

Particulars	As at		As at	
	September 30, 2019		September 30, 2018	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		7.61		12.04
<i>Adjustments for:</i>				
Depreciation and amortisation expense				
Loss / (gain) on sale of PPE (net)		73.22		108.97
Finance costs		82.48		68.45
Expenses recognised in respect of equity-settled share-based payments		-		-
Interest income		(0.80)		(0.69)
Provision for Gratuity		-		-
Operating profit before working capital changes		162.51		188.77
<i>Changes in working capital:</i> (Refer Note 40)				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Financial Assets				
Trade receivables	759.03		(54.02)	
Loans and Advances	-		-	
Other Non Current assets	(3.24)		(98.59)	
Inventories	123.06		(79.93)	
Other Current assets	30.76		(24.70)	
Other bank balances	-		(1.10)	
Other Current financial Assets	-		(16.58)	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
Trade payables	(979.22)		22.98	
Borrowings	-		-	
Other current financial liabilities	-		(116.64)	
Other current liabilities	(1.05)		125.56	
Current tax liabilities, net	7.23		10.38	
Provisions	-8.85		-	
Deferred tax on amalgamation	-		-	
Cash generated from operations		90.22		-43.87
Net income tax paid		(7.23)		(10.38)
Net cash flow from operating activities (A)		82.99		-54.24
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	(29.11)		(1.92)	
Proceeds from maturity of fixed deposits	-		-	
Interest received				
- Subsidiaries				
- Others	0.80		0.69	
Dividend income received				
- Subsidiary				
- Others - dividend from mutual funds				
Net cash (used in) / flow from investing activities (B)		(28.31)		(1.22)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	88.20		-	
Finance costs	(82.48)		(68.45)	
Repayment of Borrowings	1.03		(37.00)	
Repayment of short-term Borrowings	(0.92)		74.57	
Govt Grants	(4.30)		(3.81)	
Other equity Adjustment	(69.12)		94.94	
Net cash flow (used in) financing activities (C)		(67.59)		60.24
Net (decrease) in Cash and cash equivalents (A+B+C)		(12.91)		4.77
Cash and cash equivalents at the beginning of the year		15.89		4.08
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
Cash and cash equivalents at the end of the year (Ref Note (i) below)		2.98		8.85
* Comprises:				
Balances with Banks		1.58		6.81
Others		1.40		2.04
		2.98		8.85



S. N. S. S.